Physician profile
Khaula Raza
NPI 1982139242
$2,358.67
in general payments reported to CMS, 2019-2025
17 companies · $23.66 in 2025
The $23.66 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,836 · 2022: $324 · 2023: $134 · 2024: $41.31 · 2025: $23.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $198.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,200.00 | 2021 | |
| Glaxosmithkline, LLC. | $261.71 | 2021-2022 | |
| Novo Nordisk INC | $167.79 | 2021-2022 | |
| Abbvie INC. | $116.81 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $114.34 | 2023-2024 | |
| Amarin Pharma, INC. | $100.29 | 2021 | |
| Lilly USA, LLC | $82.35 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $67.82 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.29 | 2021 | |
| Pfizer INC. | $44.93 | 2021 | |
| Abbott Laboratories | $38.92 | 2021-2022 | |
| Optinose US, INC. | $23.70 | 2021 | |
| Seqirus USA INC | $23.66 | 2025 | Flucelvax |
| Bayer Healthcare Pharmaceuticals INC. | $19.76 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.63 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linus Health, INC. | $13.99 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaula Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.